Synthesize Bio develops generative AI models to accelerate biomedical innovation. The company's platform introduces a new paradigm for drug development by redefining what is possible in the field of genomics. GEM-1, the flagship foundation model, generates high-fidelity RNA-seq data—both bulk and single-cell—from experimental descriptions with a high degree of accuracy. The technology empowers researchers to test hypotheses and answer complex biological questions with unprecedented speed, especially in scenarios where experimental data is limited. The models and platform are designed by scientists, for scientists, ensuring they meet the specific needs of researchers. The user-friendly web platform and API access make it easy for scientists to generate the data they require using GEM-1. This AI-generated data can be seamlessly integrated with a vast repository of public data provided by the company, or with a scientist’s own experimental data. This technology is paving the way for a future where the only limit on running experiments is a scientist's imagination.